Literature DB >> 24397844

Is quantitative real time polymerase chain reaction MCAM transcript assay really suitable for prognostic and predictive management of melanoma patients?

E Capoluongo1, C Paolillo, F Vendittelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24397844     DOI： 10.1111/bjd.12818

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  3 in total

1.  Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma.

Authors:  Maria Cristina Rapanotti; Tara Mayte Suarez Viguria; Gaetana Costanza; Ilaria Ricozzi; Andrea Pierantozzi; Alessandro Di Stefani; Elena Campione; Sergio Bernardini; Sergio Chimenti; Augusto Orlandi; Luca Bianchi
Journal:  Arch Dermatol Res       Date:  2014-06-07       Impact factor: 3.017

2.  The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis.

Authors:  Anastasia De Luca; Debora Carpanese; Maria Cristina Rapanotti; Tara Mayte Suarez Viguria; Maria Antonietta Forgione; Dante Rotili; Chiara Fulci; Egidio Iorio; Luigi Quintieri; Sergio Chimenti; Luca Bianchi; Antonio Rosato; Anna Maria Caccuri
Journal:  Oncotarget       Date:  2017-02-28

Review 3.  Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.

Authors:  Maria Cristina Rapanotti; Elena Campione; Giulia Spallone; Augusto Orlandi; Sergio Bernardini; Luca Bianchi
Journal:  Cell Death Discov       Date:  2017-03-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.